Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.54 |
| ▸ | ERBB3 | P21860 | 7/20 | 0.54 |
| ▸ | ERBB4 | Q15303 | 7/20 | 0.54 |
| ▸ | TEK | Q02763 | 6/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 3/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1940603 | 0.89 | EGFR (0.64) | EGFRERBB2ERBB3ERBB4TEK | |
| SCHEMBL1941177 | 0.85 | EGFR (0.54) | EGFRERBB2ERBB3ERBB4TEK | |
| SCHEMBL1939710 | 0.84 | EGFR (0.75) | EGFRERBB2ERBB3ERBB4TEK | |
| SCHEMBL1940713 | 0.84 | EGFR (0.74) | EGFRERBB2ERBB3ERBB4TEK | |
| SCHEMBL1940561 | 0.83 | TEK (0.60) | EGFRERBB2ERBB3ERBB4TEK | |
| SCHEMBL1941729 | 0.83 | EGFR (0.60) | EGFRERBB2ERBB3ERBB4TEK | |
| SCHEMBL1940135 | 0.82 | EGFR (0.58) | EGFRERBB2ERBB3ERBB4TEK | |
| SCHEMBL1940017 | 0.81 | EGFR (0.47) | EGFRERBB2ERBB3ERBB4TEK | |
| SCHEMBL1940969 | 0.80 | EGFR (0.53) | EGFRERBB2ERBB3ERBB4TEK | |
| SCHEMBL1941309 | 0.79 | EGFR (0.54) | EGFRERBB2ERBB3ERBB4TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578751-B1 | PYRROLOPYRIMIDINE DERIVATIVES | PFIZER PROD INC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7271262-B2 | Pyrrolopyrimidine derivatives | PFIZER INC (US) | 2007-09-18 | — | — | US | disclosed |
| CN-1726218-A | Pyrrolopyrimidine derivatives | PFIZER PROD INC (US) | 2006-01-25 | — | — | CN | disclosed |
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037999-A1 | Pyrrolopyrimidine derivatives | CCNA1, CCNT1, TP53 | EGFR 2758/4885ERBB2 2738/4885ERBB3 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.